News >

Efforts Continue to Expand Immunotherapy in CRC

Danielle Bucco
Published: Monday, Nov 13, 2017

Johanna C. Bendell, MD

Johanna C. Bendell, MD
Anti–PD-1 inhibitors are effective in treating patients with microsatellite-instability high (MSI-H) colorectal cancer (CRC), with the FDA approving pembrolizumab (Keytruda) and nivolumab (Opdivo) for use in this setting.

, Bendell, a medical oncologist at Sarah Cannon Research Institute, discussed the current and emerging treatment landscape of immunotherapy for patients with CRC.

OncLive: What are some of the immunotherapy advances in CRC?

Bendell: We have seen very exciting data for patients with MSI-H CRC. These are patients who have a higher rate of mutations than others. They are very responsive to immunotherapies. In fact, we have seen FDA approvals of pembrolizumab for patients with MSI-H cancers, as well as nivolumab for MSI-H CRC, which shows what the benefit of these agents can be for these patients with CRC.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication